<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIM: Visceral adipose tissue (VAT) and liver fat (LF) are strongly associated with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>It is not known, however, how <z:mp ids='MP_0002055'>diabetes</z:mp> treatment and/or risk factor management modulates the association between VAT, LF and <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="2" pm="."><plain>The aim was to determine the level of VAT and LF in patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> according to their treatment status and achievement of the American <z:mp ids='MP_0002055'>Diabetes</z:mp> Association's (<z:chebi fb="36" ids="39048">ADA</z:chebi>) <z:mp ids='MP_0002055'>diabetes</z:mp> management goals </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: We performed a cross-sectional analysis of the baseline data of the International Study of the Prediction of Intra-Abdominal <z:e sem="disease" ids="C0028754" disease_type="Disease or Syndrome" abbrv="">Adiposity</z:e> and its Relationship with Cardiometabolic risk/Intra-Abdominal <z:e sem="disease" ids="C0028754" disease_type="Disease or Syndrome" abbrv="">Adiposity</z:e> (INSPIRE ME <z:mp ids='MP_0004157'>IAA</z:mp>), a 3-year prospective cardiometabolic imaging study conducted in 29 countries </plain></SENT>
<SENT sid="4" pm="."><plain>Patients (n = 3991) were divided into four groups: (i) those without type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> (noT2D n = 1003 men, n = 1027 women); (ii) those with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> but not treated with <z:mp ids='MP_0002055'>diabetes</z:mp> medications (T2Dnomeds n = 248 men, n = 198 women); (iii) those with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> and treated with <z:mp ids='MP_0002055'>diabetes</z:mp> medications but not yet using insulin (T2Dmeds-ins n = 591 men, n = 484 women) and (iv) those with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> and treated with insulin (T2Dmeds+ins n = 233 men, n = 207 women) </plain></SENT>
<SENT sid="5" pm="."><plain>Abdominal and liver <z:e sem="disease" ids="C0028754" disease_type="Disease or Syndrome" abbrv="">adiposity</z:e> were measured by computed tomography </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: Fewer patients with high VAT or LF achieved the <z:chebi fb="36" ids="39048">ADA</z:chebi>'s goals for <z:chebi fb="1" ids="47775">high-density lipoprotein cholesterol</z:chebi> (<z:chebi fb="0" ids="47775">HDL-C</z:chebi>) or <z:chebi fb="4" ids="17855">triglycerides</z:chebi> compared to patients with low VAT or LF </plain></SENT>
<SENT sid="7" pm="."><plain>Visceral <z:e sem="disease" ids="C0028754" disease_type="Disease or Syndrome" abbrv="">adiposity</z:e> (p = 0.02 men, p = 0.003 women) and LF (p = 0.0002 men, p = 0.0004 women) increased among patients who met fewer of the <z:chebi fb="36" ids="39048">ADA</z:chebi> treatment criteria, regardless of type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> treatment </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSION: Residual cardiometabolic risk exists among patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> characterized by elevated VAT and LF </plain></SENT>
</text></document>